Anticholinergics in the treatment of children and adults with acute asthma: A systematic review with meta-analysis

University of Santiago, Chile, CiudadSantiago, Santiago Metropolitan, Chile
Thorax (Impact Factor: 8.56). 10/2005; 60(9):740-6. DOI: 10.1136/thx.2005.040444
Source: PubMed

ABSTRACT Current guidelines recommend the use of a combination of inhaled beta(2) agonists and anticholinergics, particularly for patients with acute severe or life threatening asthma in the emergency setting. However, this statement is based on a relatively small number of randomised controlled trials and related systematic reviews. A review was undertaken to incorporate the more recent evidence available about the effectiveness of treatment with a combination of beta(2) agonists and anticholinergics compared with beta(2) agonists alone in the treatment of acute asthma.
A search was conducted of all randomised controlled trials published before April 2005.
Data from 32 randomised controlled trials (n = 3611 subjects) showed significant reductions in hospital admissions in both children (RR = 0.73; 95% CI 0.63 to 0.85, p = 0.0001) and adults (RR = 0.68; 95% CI 0.53 to 0.86, p = 0.002) treated with inhaled anticholinergic agents. Combined treatment also produced a significant increase in spirometric parameters 60-120 minutes after the last treatment in both children (SMD = -0.54; 95% CI -0.28 to -0.81, p = 0.0001) and adults (SMD = -0.36; 95% CI -0.23 to -0.49, p = 0.00001).
This review strongly suggests that the addition of multiple doses of inhaled ipratropium bromide to beta(2) agonists is indicated as the standard treatment in children, adolescents, and adults with moderate to severe exacerbations of asthma in the emergency setting.

Download full-text


Available from: Jose A Castro-Rodriguez, Aug 17, 2015
1 Follower
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Een status asthmaticus is een levensbedreigende astma-aanval waarvoor snelle en effectieve interventie is vereist. Door middel van kort en gericht onderzoek kan de ernst van de astma-aanval worden ingeschat. Belangrijke tekenen van een levensbedreigende aanval zijn verminderd bewustzijn, dreigende uitputting, zuurstofsaturatie onder 85% en een verzwakt ademgeruis (‘stille thorax’). De ernst van de astma-aanval kan worden uitgedrukt in een astmascore.Voor de behandeling moet de relatieve bijdrage van luchtweginflammatie, bronchoconstrictie en mucusplugging worden ingeschat. De pijlers van de behandeling van een status asthmaticus in de alge-mene pediatrische praktijk zijn zuurstof, continu vernevelen met salbutamol, systemische corticosteroïden, magnesiumsulfaat i.v. en eventueel salbutamol i.v. Mocht bovenstaande niet voldoende zijn, dan moeten in nauw overleg met de kinder-IC de volgende stappen worden besproken. Redenen voor overplaatsing naar een kinder-IC zijn dreigende uitputting en/of respiratoire insufficiëntie, noodzaak voor beademing en intraveneuze toediening van salbutamol. Severe acute asthma (SAA) is life threatening and warrants fast and effective intervention. The severity of SAA can be assessed through a focused and concise clinical examination. Important signs of a life threatening attack are decreased consciousness, imminent exhaustion, oxygen saturation below 85% and diminished air movement on auscultation (silent chest). The severity of SAA can be expressed in an asthma score. The relative contribution of airway inflammation, bronchoconstriction and mucusplugging must be weighed for treatment choices. The pillars of treatment of SAA in the general pediatric practice are oxygen, continuous nebulization of salbutamol, systemic corticosteroids, intravenous magnesium sulphate and perhaps intravenous salbutamol. Further steps in treatment of unresponsive SAA should be initiated in consultation with the pediatric intensive care. Reasons for transfer to a pediatric intensive care are imminent exhaustion and/or respiratory insufficiency, need for mechanical ventilation and intravenous salbutamol.
    Tijdschrift voor kindergeneeskunde 12/2009; 77(6):269-274. DOI:10.1007/BF03086408
Show more